Sign in
Taking peoplePhase 2

Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis

Key facts

Who runs it
RWTH Aachen University
Where
Austria and Germany13 sites in 2 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
20 Nov 2017
Expected to end
Mar 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pentaglobin®/Standard of Care
Record updated
11 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • The patient is diagnosed with secondary or quaternary peritonitis
  • The time of the surgical infectious source control is within 6 hours of indication (defined as date and time of registration for surgical or minimal invasive procedure)
  • Sepsis and / or septic shock (according to the current sepsis guideline of the German Sepsis Society)
  • SOFA Score ≥ 8
  • The concentration of IL-6 is ≥ 1000 pg / ml
  • Treatment with antibiotics is started within 12 hours of admission to the Intensive Care Unit
  • The informed consent form has been signed by the patient and / or by his legal representative (such as his spouse, an health care proxy authorized or a legal representative) or by a consultant physician

Who cannot take part

  • The patient has any contraindication to study drug
  • Patients with a life expectancy of less than 90 days due to medical conditions unrelated to peritonitis nor with sepsis and / or septic shock
  • The patient has known chronic renal dysfunction requiring dialysis (creatinine ≥ 3.4 mg / dl or creatinine clearance ≤ 30 mL/min/1.73 m²)
  • The patient is a minor (< 18 years of age)
  • For female patients: The patient is pregnant or breastfeeding
  • The patient has acute, primarily non-infectious pancreatitis or mediastinitis
  • The patient has a BMI > 40
  • The patient has participated in another clinical trial within the last 30 days
  • The patient is in a dependent or employment relationship with the sponsor or investigator
  • The patient is institutionalized by court or government order

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Peritonitis or sepsis or septic shock

This trial is currently available in Austria and Germany.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this prospective, randomized, controlled trial is to provide evidence for adjuvant IgGAM treatment with regard to

Read full original descriptionShow less

1. Improvement of patient outcomes for peritonitis. Improvement in outcome will be determined by scores such as MOF, SOFA and survival. 2. Identification of biomarkers (including immunoglobulin levels, HLA-DR, NF-kB1 and other immunological biomarkers) to identify patient subpopulations that benefit most from IgGAM treatment. These patients will form the basis for a further randomized, controlled, double-blind Phase III trial (RCT) to demonstrate the benefit of this treatment. 3. In addition, these biomarkers could help to guide a targeted, i.e. "personalized", adjuvant therapy with Pentaglobin® (IgGAM) in the indication of peritonitis.

The 2 groups in the trial

  • Control armNo study treatment, for comparison

    Standard of Care treatment

  • Verum armExisting treatment, for comparison

    Standard of Care treatment + Pentaglobin®

    Treatment: Pentaglobin®/Standard of Care

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from NCT03334006, who can take part
Publications
Record updated
11 June 2026